Small Molecule Inhibitors Targeting MTDH-SND1 Protein Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for small molecule inhibitors of the MTDH-SND1 protein-protein interaction to treat cancer, particularly to inhibit metastasis, sensitize cancer to treatment, and promote T-cell activation and infiltration.
Innovation Solution
Development of compounds that inhibit the MTDH-SND1 interaction, including specific structural formulas and their pharmaceutically acceptable salts, which are used to treat cancer by inhibiting metastasis, sensitizing cancer to therapy, and promoting T-cell activation and infiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide inhibitors are used to block MTDH-SND1 interaction, then cancer treatment efficacy is improved, but molecular complexity and manufacturing difficulty increase
Solution Approach 1:
The patent transforms the inhibitor from a peptide (complex structure) to a small molecule compound (simpler structure) by changing molecular parameters including size, composition, and structural complexity while maintaining the ability to inhibit MTDH-SND1 interaction and treat cancer
2Ease of manufacture
If small molecule inhibitors are developed, then manufacturing ease is improved, but inhibition efficacy may be reduced compared to peptide inhibitors
Solution Approach 1:
The small molecule inhibitors are designed with optimized molecular parameters including specific functional groups, molecular weight, and structural features that enable both ease of manufacture through standard pharmaceutical processes and effective inhibition of the MTDH-SND1 protein-protein interaction
Data Source
AI summary
Provided herein are methods of using small molecule inhibitors of the MTDH-SND1 protein-protein interaction, such as a compound of the following structural formula: (I) or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., X1, X2, X3, X4, X5, X6, X7, R3, R4, m) are as described herein. The compounds described herein can be used, for example, to treat cancer as, for example, by inhibiting metastasis of a cancer, sensitizing a cancer to treatment with an additional therapy, and/or promoting T-cell activation and/or infiltration in response to a cancer.